|1.||Rose-John, Stefan: 14 articles (10/2015 - 09/2003)|
|2.||Nishimoto, Norihiro: 13 articles (04/2014 - 12/2002)|
|3.||Kishimoto, Tadamitsu: 11 articles (04/2014 - 07/2003)|
|4.||Jones, Simon A: 8 articles (11/2014 - 09/2003)|
|5.||Mihara, Masahiko: 7 articles (01/2011 - 06/2004)|
|6.||Ohsugi, Yoshiyuki: 6 articles (08/2010 - 07/2005)|
|7.||Yoshizaki, Kazuyuki: 6 articles (06/2009 - 12/2002)|
|8.||Scheller, Jürgen: 5 articles (09/2014 - 09/2006)|
|9.||Anderson, Kenneth C: 5 articles (12/2012 - 06/2005)|
|10.||Ando, Yukio: 4 articles (11/2015 - 08/2009)|
09/01/2014 - "To evaluate safety and efficacy of weekly (qw) and every other week (q2w) dosing of sarilumab, a fully human anti-interleukin 6 receptor α (anti-IL-6Rα) monoclonal antibody, for moderate-to-severe rheumatoid arthritis (RA). "
07/01/2003 - "Toxicity, pharmacokinetics, and dose-finding study of repetitive treatment with the humanized anti-interleukin 6 receptor antibody MRA in rheumatoid arthritis. "
02/01/2015 - "Chemerin and cardiovascular risk in rheumatoid arthritis after interleukin 6 receptor blockade."
09/01/2012 - "Both innate and adaptative immunity demonstrated their respective cornerstone position in rheumatoid arthritis, since targeted treatments has been efficiently developed against TNF-α, IL-6 receptor, IL-1β, CD20 B cells and T-cell/Dendritic cell interactions."
01/01/2012 - "Sleep disturbances and interleukin 6 receptor inhibition in rheumatoid arthritis."
|2.||Juvenile Rheumatoid Arthritis (Juvenile Idiopathic Arthritis)
09/01/1998 - "A possible role for soluble IL-6 receptor in the pathogenesis of systemic onset juvenile chronic arthritis."
05/01/1994 - "By using a sandwich ELISA, soluble human IL-6 receptor (sIL-6 R) levels were measured in the sera of 20 healthy children and of 25 patients with systemic juvenile rheumatoid arthritis (JRA). "
01/01/2005 - "Open label phase II trial of single, ascending doses of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis: proof of principle of the efficacy of IL-6 receptor blockade in this type of arthritis and demonstration of prolonged clinical improvement."
04/01/2014 - "Longterm safety and effectiveness of the anti-interleukin 6 receptor monoclonal antibody tocilizumab in patients with systemic juvenile idiopathic arthritis in Japan."
03/01/2013 - "Currently, tocilizumab, which binds the IL-6 receptor, is licensed for treatment in active, moderate to severe disease in RA and systemic juvenile idiopathic arthritis (JIA). "
|3.||Giant Lymph Node Hyperplasia (Castleman's Disease)
11/01/2000 - "In this review, the new therapeutic strategy for Castleman's disease and RA using humanized antibody to human IL6 receptor, MRA, is discussed."
01/01/2015 - "Discovery of Innovative Therapies for Rare Immune-Mediated Inflammatory Diseases via Off-Label Prescription of Biologics: The Case of IL-6 Receptor Blockade in Castleman's Disease."
01/01/2014 - "Short-term efficacy of the IL6 receptor antibody tocilizumab in patients with HIV-associated multicentric Castleman disease: report of two cases."
01/01/2013 - "We hypothesized that interleukin-6/interleukin-6 receptor/gp130 polymorphisms contribute to increased interleukin-6 and/or other components of the interleukin-6 signaling pathway in HIV-negative Castleman Disease patients. "
12/01/2005 - "[Pharmacological and clinical profile of anti-human IL-6 receptor antibody (tocilizumab, ACTEMRA), a novel therapeutic drug for Castleman's disease]."
01/01/2012 - "Preliminary data also suggest efficacy of the IL-6 receptor inhibitor tocilizumab in patients with large-vessel vasculitis. "
08/01/2013 - "We performed a systematic literature search (PubMed until July 2012) using the terms "tocilizumab," "anti-IL-6-receptor," "polymyalgia rheumatica," "giant cell arteritis", and "large-vessel vasculitis" to identify published reports of patients with PMR treated with TCZ. "
01/01/2002 - "The plasma levels of TNFalpha, its soluble receptor p75 (sTNF-RII), IL-6, and the soluble IL-6 receptor (sIL-6R) were measured using ELISA in 17 patients with ANCA-positive renal vasculitis (12 active - ANCA-A, 7 in remission ANCA-R), 9 patients with active lupus nephritis (LN), and 5 healthy subjects. "
05/04/1998 - "Plasma levels of TNF alpha, its soluble receptor p75 (sTNF-RII), IL-6 and soluble IL-6 receptor (sIL-6R) were measured using ELISA in 17 pts with ANCA-positive renal vasculitis (12 active-ANCA-A, 7 in remission ANCA-R), 9 pts with active lupus nephritis (LN) and 5 healthy subjects. "
01/01/2013 - "Encouraging preliminary results have been obtained with the IL-6 receptor (IL-6R) antagonist tocilizumab for the treatment of large-vessel vasculitides, including both giant cell arteritis and Takayasu arteritis, and the aortitis of Cogan syndrome and relapsing polychondritis. "
09/01/2015 - "Accordingly, targeted inhibition of the IL6 receptor and its downstream effectors JAK1 and STAT3 dramatically reduced tumor cell growth. "
02/15/2014 - "Treating mice with soluble IL-6 receptor fusion protein or silencing STAT3 in tumor cells significantly reduced prostate tumor growth and CSCs. "
01/01/2014 - "To interfere with IL-6-dependent diseases, targeting IL-6 receptor (IL-6R)-presenting tumor cells using aptamers might be a valuable strategy to broaden established IL-6- or IL-6R-directed treatment regimens. "
07/01/2012 - "Interleukin 6 receptor was expressed across multiple cancer cell lines. "
05/01/2012 - "The interleukin 6 receptor is a direct transcriptional target of E2F3 in prostate tumor derived cells."
|2.||Interleukin-6 (Interleukin 6)
|3.||Antineutrophil Cytoplasmic Antibodies (ANCA)
|4.||Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
|5.||A 7 (A-7)
|8.||Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
|1.||Drug Therapy (Chemotherapy)
|2.||Transplantation (Transplant Recipients)